M. Vijey Aanandhi

Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19

D Praveen, Ranadheer Chowdary Puvvada, M. Vijey Aanandhi · International Journal of Antimicrobial Agents · 2020 · 95 citations · Full text

Antiviral Drug Development, Antiviral Therapy, Ideal Option +5

Association of vitamin C status in diabetes mellitus: prevalence and predictors of vitamin C deficiency

D Praveen, Ranadheer Chowdary Puvvada, M. Vijey Aanandhi · Future Journal of Pharmaceutical Sciences · 2020 · 29 citations · Full text

Nutrition, Oxidative Stress, Obesity +18

Analytical method development and validation for the simultaneous estimation of lopinavir and ritonavir by RP-HPLC method in tablet dosage form

Akella Anuradha, M. Vijey Aanandhi, Afroz Patan · Annals of Phytomedicine An International Journal · 2023 · 23 citations · Full text

Pharmacotherapy, Antiviral Drug, Simultaneous Estimation +18

Molecular docking studies on naturally occurring selected flavones against protease enzyme of Dengue virus.

E. Shanmugapriya, V. Ravichandiran, M. Vijey Aanandhi · Research Journal of Pharmacy and Technology · 2016 · 18 citations · Full text

Dengue Virus, Molecular Virology, Biochemistry +12

Analytical method development and validation of rifaximin and ornidazole in bulk and combined tablet dosage form as per ICH guidelines

K. Subhamalar, M. Vijey Aanandhi, Afroz Patan · Annals of Phytomedicine An International Journal · 2023 · 17 citations · Full text